Non-coding RNAs Involved in Cancer Chemoresistance
A special issue of Non-Coding RNA (ISSN 2311-553X). This special issue belongs to the section "Clinical Applications of Non-Coding RNA".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 19605
Special Issue Editors
2. Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M1 7DN, UK
Interests: microRNA; miRNA; long noncoding RNA; lncRNA; noncoding RNA; ncRNA; cancer; tumour; chemoresistance; drug resistance
Special Issue Information
Dear Colleagues,
In the past two decades, following the discovery of the RNA interference pathway by Fire and Mello, the biological and clinical roles of noncoding RNA families of the ‘dark matter’ of the genome have evolved rapidly. Presently, these families include microRNAs and long noncoding RNA families that are already acknowledged to have widespread implications for all physiological processes within the mammalian cell through their highly effective gene regulatory roles. Consequently, noncoding RNA family elements can—when dysregulated—allow for the pathogenesis and progression of a myriad of medical conditions, including cancer. Furthermore, on focusing on the noncoding RNA influences in cancer, specific tumour characteristics can be exacerbated or inhibited through noncoding RNA direction. This Special Issue aims to delve deeper and consolidate all recent global research efforts (research articles/reviews) for specific noncoding RNA biomarker discovery and validation, including mechanistic implications of noncoding RNAs in the development (and regulation) of the drug resistant tumour phenotype, for possible theranostic exploitation in the near future.
Dr. Duncan Ayers
Dr. Ali Rihani
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microRNA
- miRNA
- Long noncoding RNA
- lncRNA
- noncoding RNA
- ncRNA
- Cancer
- Tumor
- Chemoresistance
- Drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.